Testosterone metabolism, dose–response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men

References

• Bagatell CJ, Bremner WJ. Androgens in aging men: do men benefit from testosterone replace- ment? J Anti-Aging Med 1998;1:359–64
   Google Scholar
• Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl 1999;22:300–6
   PubMed Web of Science ®Google Scholar
• Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000;75:77–82
   Google Scholar
• Comhaire FH. Andropause: hormone replace- ment therapy in the ageing male. Eur Urol 2000;38:655–62
   PubMed Web of Science ®Google Scholar
• Hayes FJ. Testosterone – fountain of youth or drug of abuse? [Editorial]. J Clin Endocrinol Metab 2000;85:3020–3
   PubMedGoogle Scholar
• Morales A, Heaton JPW, Caron III CC. Andropause: a misnomer for a true clinical entity. J Urol 2000;163:705–12
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab 2001;86:2380–90
   PubMed Web of Science ®Google Scholar
• Basaria S, Wahlstrom JT, Dobs AS. Anabolic- androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86:5108–17
   PubMed Web of Science ®Google Scholar
• Lejeune H. Age-related androgen deficiency. Andrologie 2001;11:241–38
   Google Scholar
• Baulieu EE. Androgens and aging men. Mol Cell Endocrinol 2002;198:41–9
   PubMed Web of Science ®Google Scholar
• Lunenfeld B. Replacement therapy in the aging male. J Endocrinol Invest 2002;25:2–9
   PubMedGoogle Scholar
• Wilson JD, Leihy MW, Shaw G, Renfree MB. Androgen physiology: unsolved problems at the millennium. Mol Cell Endocrinol 2002;198:1–5
   PubMed Web of Science ®Google Scholar
• De Ligniéres B. L’andropause et sa prise en charge chez l’homme agé. Dossier Geriatrie 2002;31:1750–9
   Google Scholar
• Oettel M, Hübler D, Patchev P. Selected aspects of endocrine pharmacology of the aging male. Exp Gerontol 2003;38:189–98
   PubMedGoogle Scholar
• Vastag B. Many questions, few answered for testosterone replacement therapy. J Am Med Assoc 2003;298:971–4
   Google Scholar
• Butenandt A. Aufgaben und Ziele der Hormonforschung. Pharmazeutische Industrie 1941;8:43–5
   Google Scholar
• Gambineri A, Pasquali R. Testosterone therapy in men: clinical and pharmacological perspec- tives. J Endocrinol Invest 2000;23:196–214
   PubMed Web of Science ®Google Scholar
• Bhasin S, Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997;82:3–8
   PubMed Web of Science ®Google Scholar
• Anawalt BD, Amory JK, Wang C, Swerdloff RS, Dobs AS, Meikle AW, et al. A pharma- cokinetic study of oral testosterone undecanoate (Org 538). J Androl 2002;(Suppl):37
   Google Scholar
• Tan RS, Culberson JW. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 2003; 45:15–21
   PubMed Web of Science ®Google Scholar
• Yialamas MA, Hayes FJ. Androgens and the ageing male and female. Best Pract Res Clin Endocrinol Metab 2003;17:223–36
   PubMed Web of Science ®Google Scholar
• Oettel M. Testosteron. In Stoffe P-Z, von Bruchhausen F, Dannhardt G, Ebel S, Frahm AW, Hackenthal E, Holzgrabe U, eds. Hager’s Handbuch der Pharmazeutischen Praxis. Berlin: Springer-Verlag, 1994:820–2
   Google Scholar
• Gobinet J, Poujol N, Sultan C. Molecular action of androgens. Mol Cell Endocrinol 2002; 198:15–24
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23:175–200
   PubMed Web of Science ®Google Scholar
• Saartok T, Dahlberg E, Gustaffson J-A. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984;114:2100–6
   PubMedGoogle Scholar
• Hsiao PW, Thin TH, Lin DL, Chang C. Differential regulation of testosterone vs. 5α- dihydrotestosterone by selective androgen response elements. Mol Cell Biochem 2000; 206:169–75
   PubMedGoogle Scholar
• Winters S. Androgens and anti-androgens. In Brody TM, Larner J, Minneman KP, eds. Human Pharmacology: Molecular to Clinical, 3rd edn. St. Louis: Mosby, 1998:519–31
   Google Scholar
• Larionov AA, Vasyliev DA, Mason JI, Howie AF, Berstein LM, Miller WR. Aromatase in skeletal muscle. J Steroid Biochem Mol Biol 2003;84:485–92
   PubMed Web of Science ®Google Scholar
• Simpson ER, Davis SR. Minireview. Aromatase and the regulation of estrogen biosynthesis – some new perspectives. Endocrinology 2001;142:4589–94
   PubMed Web of Science ®Google Scholar
• Zagar Y, Liebherr M. Signaling cross talk in the rapid action of androgens. Presented at the 6th European Congress of Endocrinology, Lyon, France, 26–30 April 2003:abstr O–19
   Google Scholar
• Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins innongenomic androgen actions. Mol Endocrinol2002;16:2181–7
   PubMedGoogle Scholar
• Papakonstanti EA, Kampa M, Castanas E, Stounaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 2003;17:870–81
   Google Scholar
• Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148:281–92
   PubMed Web of Science ®Google Scholar
• Lutz LB, Jamnongjit M, Yang WH, Jahani D, Gill A, Hammes SR. Selective modulation of geno- mic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol 2003; 17:1106–16
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, Yarasheski K, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407–13
   PubMed Web of Science ®Google Scholar
• Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementa- tion. J Steroid Biochem Mol Biol 2003;in press
   Google Scholar
• Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee ML, et al. Testosterone induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002;283:E154–64
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition para- meters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839–53
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7
   PubMed Web of Science ®Google Scholar
• Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, et al. Testosterone dose- dependently increases maximal voluntary strength and leg power, but does not affect fatiguability or specific tension. J Clin Endocrinol Metab 2003;88:1478–85
   PubMed Web of Science ®Google Scholar
• Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose- response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172–81
   PubMed Web of Science ®Google Scholar
• Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic- androgenic steroids. Clin Ther 2001;23:1355–90
   PubMed Web of Science ®Google Scholar
• Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81:3469–75
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998;275:E865–71
   Google Scholar
• Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndorn DN, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999;84:2705–11
   PubMed Web of Science ®Google Scholar
• Crawford BAL, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo- controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003;88:3167–76
   PubMed Web of Science ®Google Scholar
• Bhasin S, Woodhouse L, Storer TW. Hormones and sport. Proof of the effect of testosterone on skeletal muscle. J Endocrinol 2001;170:27–38
   PubMed Web of Science ®Google Scholar
• Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994;267:E331–6
   PubMed Web of Science ®Google Scholar
• Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269:E820–6
   PubMed Web of Science ®Google Scholar
• Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002;87:5649–57
   PubMed Web of Science ®Google Scholar
• Hayes VY, Urban RJ, Jiang J, Marcell TJ, Helgeson K, Mauras N. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects. J Clin Endocrinol Metab 2001; 80:2211–19
   Google Scholar
• Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886–92
   PubMed Web of Science ®Google Scholar
• Gentili A, Mulligan T, Godschalk M, Clore J, Patrie J, Iranmanesh A, et al. Unequal impact of short-term testosterone repletion on the somato- tropic axis of young and older men. J Clin Endocrinol Metab 2002;87:825–34
   PubMedGoogle Scholar
• Kamel HK, Maas D, Duthie EH Jr. Role for hormones in the pathogenesis and management of sarcopenia. Drugs Aging 2002;19:865–77
   PubMed Web of Science ®Google Scholar
• McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94:12457–61
   PubMed Web of Science ®Google Scholar
• Gonzales-Cadavid NF, Taylor WE, Yaresheski K, Sinha-Hikim I, Ma K, Ezzat S, et al. Organiza- tion of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998; 95:14938–43
   PubMedGoogle Scholar
• Mallidis C, Bhasin S, Matsumoto A, Shen R, Gonzales-Cadaid NF. Skeletal muscle myostatin in a rat model of aging-associated sarcopenia. Proceedings of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, June 1999:abstr OR-9-1
   Google Scholar
• Yaresheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzales-Cadavid NF. Serum myostatin-immunoreactive proteins increased with muscle wasting and advanced age. Proceed- ings of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, June 1999:abstr OR-9-2
   Google Scholar
• Shivji R, Bhasin S, Byhower F, Tarnuzzer RW, Grant M, Shen R, et al. Myostatin and IGF-1 and-2 expression in muscle wasting resulting from exposure to the microgravity environment of a space shuttle flight. Proceedings of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1999, OR-32-2
   Google Scholar
• Marcell TJ, Harman SM, Urban RJ, Metz DD, Rodgers BD, Blackman MR. Comparison of GH- IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. Am J Physiol Endocrinol Metab 2001; 281:E1159–74
   Google Scholar
• Tincello DG, Saunders PTK, Hodgins MB, Simpson NB, Edwards CRW, Hargreave TB, et al. Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone therapy in patients with partial androgen insensitivity. Clin Endocrinol 1997;46:497–506
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolf RR. Testosterone normal- ization in severe burns ameliorates muscle catabolism. FASEB J 2000;14:A797
   Google Scholar
• Sheffield-Moore M. Androgens and the control of skeletal muscle protein synthesis. Ann Med 2000;32:181–6
   PubMed Web of Science ®Google Scholar
• Raaka BM, Finnerty M, Samuels HH. The glu- cocorticoid antagonist 17-methyltestosterone binds to the 10 S glucocorticoid receptor and blocks agonist-mediated dissociation of the 10 S oligomer to the 4 S deoxyribonucleic acid- binding subunit. Mol Endocrinol 1989;3:332–41
   PubMedGoogle Scholar
• Danhaive PA, Rosseau GG. Binding of gluco- corticoid antagonists to androgen and glucocorti- coid hormone receptors in rat skeletal muscle. J Steroid Biochem 1986;24:481–7
   PubMedGoogle Scholar
• Danhaive PA, Rosseau GG. Evidence for sex- dependent anabolic response to androgenic steroids mediated by muscle glucocorticoid receptors in the rat. J Steroid Biochem 1988;29:575–81
   PubMedGoogle Scholar
• Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318:635–41
   Google Scholar
• Wu FC. Endocrine aspects of anabolic steroids. Clin Chem 1997;43:1289–92
   PubMedGoogle Scholar
• Hickson RC, Czerwinski SM, Falduto MT, Young AP. Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Med Sci Sports Exerc 1990;22:331–40
   PubMedGoogle Scholar
• Yen PM, Liu Y, Palvimo JJ, Trifiro M, Whang J, Pinsky L, et al. Mutant and wild-type andro- gen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription. Mol Endocrinol 1997;11:162–71
   PubMedGoogle Scholar
• Laseter JT, Russel JA. Anabolic steroid-induced tendon pathology: a review of the literature. Med Sci Sports Exerc 1991;23:1–3
   PubMed Web of Science ®Google Scholar
• Stannard JP, Bucknell AL. Rupture of the triceps tendon associated with steroid injections. Am J Sports Med 1993;21:482–5
   PubMed Web of Science ®Google Scholar
• Barceló AC, Olivera MI, Bozzini C, Alippi RM, Bozzini CE. Androgens and erythropoiesis. Induction of erythropoietin-hypersecretory state and effect of finasteride on erythropoietin secre- tion. Comp Haematol Int 1999;9:1–6
   Google Scholar
• Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of trans- dermal dihydrotestosterone on the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467–72
   PubMed Web of Science ®Google Scholar
• Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J Clin Endocrinol Metab 1997;82:3793–6
   PubMed Web of Science ®Google Scholar
• Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12 months randomized controlled study. J Clin Endocrinol Metab 1997; 82:1661–7
   PubMed Web of Science ®Google Scholar
• Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitu- tion therapy on erythropoiesis. Eur J Med Res 1997; 2:293–8
   Google Scholar
• Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficiency, and safety of a permeation enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone- enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469–78
   PubMed Web of Science ®Google Scholar
• Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythro- poietin production in the murine kidney, brain, and uterus. Am J Physiol Endrocrinol Metab 2000; 279:E1242–8
   Web of Science ®Google Scholar
• Blobel GA, Sieff CA, Orkin SH. Ligand- dependent repression of the erythroid trans- cription factor GATA-1 by the estrogen receptor. Mol Cell Biol 1995;15:3147–53
   PubMed Web of Science ®Google Scholar
• Tan KCB, Shiu SWM, Pang RWC, Kung AWC. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol 1998;48:187–94
   PubMedGoogle Scholar
• Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM. Differential contri- bution of testosterone and estradiol in the deter- mination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166:95–102
   PubMed Web of Science ®Google Scholar
• Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Endocrinol Metab 2003;284:1112–18
   PubMed Web of Science ®Google Scholar
• Bhasin S, Buckwalter JG. Testosterone supple- mentation in older men: a rational idea whose time has not yet come. J Androl 2001;22:718–31
   PubMedGoogle Scholar
• Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111:261–9
   PubMed Web of Science ®Google Scholar
• Singh AB, Hsia S, Alaupovic P, Sinha-Hikum I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of testosterone on insulin sensi- tivity, plasma lipids, apolipoproteins, and C- reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87:136–43
   PubMed Web of Science ®Google Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001;111:255–60
   PubMed Web of Science ®Google Scholar
• Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313–40
   PubMed Web of Science ®Google Scholar
• Hak AE, Wittemann JCM, de Jong FH, Geerlings MI, Hofmann A, Pols HAP. Low levels of endo- genous androgens increase the risk of athero- sclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002;87:3632–9
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt CJ, Agawal S, Rajkumar C. Testosterone suppression in men with prostate cancer is associated with increased arterial stiff- ness. Aging Male 2002;5:216–22
   PubMedGoogle Scholar
• Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 2003;26:1869–73
   PubMedGoogle Scholar
• Perusquia M. Androgen-induced vasorelaxation: a potential vascular protective effect. Exp Clin Endocrinol Diabetes 2003;111:55–9
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Nieschlag E. Review about ‘Androgen-induced vasorelaxation: a potential vascular protective effect’ by M Perusquia. Exp Clin Endocrinol Diabetes 2003:111:55–9
   PubMedGoogle Scholar
• Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 2002;87:5030–7
   PubMed Web of Science ®Google Scholar
• Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, Celermajer S. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol 2003;59:62–7
   PubMed Web of Science ®Google Scholar
• Heemers H, Vanderhoydonc F, Roskams T, Shechter I, Heyns W, Verhoeven G, et al. Andro- gens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 2003;205:21–31
   Google Scholar
• Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 2003;300:167–71
   PubMed Web of Science ®Google Scholar
• Kaplan N. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceri- demia and hypertension. Arch Int Med 1989; 149:1514–20
   PubMed Web of Science ®Google Scholar
• Rolf C, von Eckardstein S, Koken U, Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol 2002;146:505–11
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Benova Z, Christov VG. Testos- terone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1–7
   PubMedGoogle Scholar
• Björntorp P. The regulation of adipose tissue dis- tribution in humans. Int J Obes 1996;20:291–302
   PubMed Web of Science ®Google Scholar
• Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999;48:590–6
   PubMed Web of Science ®Google Scholar
• Kalintchenko S. The role of androgens in the treatment of obesity in men. In 3rd International Conference of the Andropause Society. Androgens and Men’s Health. London, UK: The Royal Society, 2003:40
   Google Scholar
• Oettel M. Estrogens and antiestrogens in the male. In Oettel M, Schillinger E, eds. Handbook of Experimental Pharmacology. Berlin: Springer- Verlag, 1999;135/II:505–71
   Google Scholar
• Oettel M. Is there a role for estrogens in the maintenance of men’s health? Aging Male 2002; 5:248–57
   PubMedGoogle Scholar
• Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5:98–102
   PubMedGoogle Scholar
• De Ronde W, Pols HAP, van Leeuwen JPTM, de Jong FH. The importance of oestrogens in males. Clin Endocrinol 2003;58:529–42
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Toorians AW. Significance of oestro- gen in male (patho) physiology. Ann Endocrinol 2003;64:126–35
   PubMed Web of Science ®Google Scholar
• Brain PF, Poole AE. The role of endocrines in isolation-induced intermale fighting in albino laboratory mice. II. Sex steroid influences in aggressive mice. Aggress Behav 1976;2:55–76
   Google Scholar
• Kurischko A, Oettel M. Androgen-dependent fighting behaviour in male mice. Endokrinologie 1977;70:1–5
   PubMedGoogle Scholar
• Martinez-Sanchis A, Salvador A, Moya-Albiol L, González-Bono E, Simón VM. Effects of chronic treatment with testosterone propionate on aggression and hormonal levels in intact male mice. Psychoneuroendocrinology 1998;23:275–93
   PubMedGoogle Scholar
• McGinnis MY, Lumia AR, Breuer ME, Possidente B. Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids. Horm Behav 2002;41:101–10
   PubMedGoogle Scholar
• Oettel M, Kurischko A. Physiologisch- endokrinologische Studien zum Aggressions- verhalten von Mäuseböcken. Z Versuchtstierk 1978;20:186–93
   PubMedGoogle Scholar
• Martínez-Sanchis S, Arnedo MT, Salvador A. Anti-aggressive effect of high doses of testos- terone propionate is modulated by the type of opponent. Med Sci Res 1999;27:765–7
   Google Scholar
• Oettel M, Kurischko A. Maintenance of aggres- sive behaviour in castrated mice by sex steroids: modification by neonatal injections of gonadal hormones. In Dörner G, Kawakami M, eds. Hor- mones and Brain Development. Amsterdam: Elsevier/North-Holland Biomedical Press, 1978:49–56
   Google Scholar
• Frye CA, Rhodes ME, Walf A, Harney JP. Testosterone enhances aggression of wild-type mice but not those deficient in type I 5α- reductase. Brain Res 2002;948:165–70
   PubMedGoogle Scholar
• Mazur A, Booth A. Testosterone and dominance in men. Behav Brain Sci 1998;21:353–97
   PubMed Web of Science ®Google Scholar
• Aromäki AS, Lindman RE, Eriksson CJP. Testosterone, aggressiveness, and antisocial personality. Aggress Behav 1999;25:113–23
   Web of Science ®Google Scholar
• Räsänen P, Hakko H, Visuri S, Paanila J, Kapanen P, Suomela T, et al. Serum testosterone levels, mental disorders and criminal behaviour. Acta Psychiatr Scand 1999;99:348–52
   PubMed Web of Science ®Google Scholar
• Campbell A, Muncer S, Odber J. Aggression and testosterone: testing a bio-social model. Aggress Behav 1997;23:229–38
   Web of Science ®Google Scholar
• Archer J, Birring SS, Wu FCW. The association between testosterone and aggression among young men: empirical findings and a meta- analysis. Aggress Behav 1998;24:411–20
   Web of Science ®Google Scholar
• Blanco C, Ibánez A, Blanco-Jerez CR, Baca- Garcia E, Sáiz-Ruiz J. Plasma testosterone and pathological gambling. Psychiatry Res 2001;105:117–21
   PubMed Web of Science ®Google Scholar
• Aromäki AS, Lindman RE, Eriksson CJP. Testosterone, sexuality and antisocial personality in rapists and child molesters: a pilot study. Psychiatry Res 2002;110:239–47
   PubMedGoogle Scholar
• Christiansen K. Behavioural effects of androgen in men and women. J Endocrinol 2001;170:39–48
   PubMed Web of Science ®Google Scholar
• Huebler D, Christoph A, Schubert M, Oettel M, Ernst M, Mellinger U, et al. Effect of a new long-acting testosterone undecanoate (TU) formulation vs. testosterone enanthate (TE) for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men. Int J Impot Res 2001;13(Suppl 1):S31
   Google Scholar
• Kouri EM, Lukas SE, Pope HG, Oliva PS. Increased aggressive responding in malevolunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 1995;40:73–9
   PubMed Web of Science ®Google Scholar
• Pope HG, Kouri EM, Hudson JI. Effects of supraphysiological doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry 2000;57:133–40
   PubMed Web of Science ®Google Scholar
• Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry 1999;45:254–60
   PubMed Web of Science ®Google Scholar
• O’Connor DB, Archer J, Hair WM, Wu FCW. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Psychol Behav 2002;75:557–66
   Google Scholar
• Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, et al. The effects of supra- physiological doses of testosterone on angry behavior in healthy eugonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81:3754–8
   PubMed Web of Science ®Google Scholar
• Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDionald V, et al. Testosterone replacement therapy improves mood in hypo- gonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81:3578–83
   PubMed Web of Science ®Google Scholar
• Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, et al. Androgen – behaviour correlations in hypo- gonadal men and eugonadal men. Horm Behav 1998;33:85–94
   PubMed Web of Science ®Google Scholar
• Anderson RA, Martin CW, Kung AWC, Everington D, Pun TC, Tan KCB, et al. 7αMethyl-19-nortestosterone maintains sexual behaviour and mood in hypogonadal men. J Clin Endocrinol Metab 1999;84:3556–62
   PubMed Web of Science ®Google Scholar
• Svetec DA, Canby ED, Thompson IM, Sabenegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypo- gonadal men with erectile dysfunction. J Urol 1997;158:1775–7
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges C. Studies on prostatic cancer. Effect of castration, of estrogen and androgen injections in serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7
   Google Scholar
• Sciarra F. Sex steroids and epidermal growth factor in benign prostatic hyperplasia (BPH). Ann NY Acad Sci 1995;761:66–78
   PubMed Web of Science ®Google Scholar
• Gerstenbluth RE, Maniam PH, Corty EW, Seftel AD. Prostate-specific antigen changes in hypo- gonadal men treated with testosterone replace- ment. Andrology 2002;23:922–6
   Google Scholar
• Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, et al. Relationship of serum androgens and estrogens to prostate cancer risk: results from prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998; 7:1069–74
   PubMed Web of Science ®Google Scholar
• López-Otín C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998;19:365–96
   PubMed Web of Science ®Google Scholar
• Heikkilä R, Aho K, Heliövaara M, Hakama M, Marniemi J, Reunanen A, et al. Serum testos- terone and sex hormone-binding globulin con- centrations and the risk of prostate carcinoma. Cancer 1999;86:312–15
   PubMed Web of Science ®Google Scholar
• Slater S, Oliver RTD. Testosterone – its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431–9
   PubMed Web of Science ®Google Scholar
• Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113–20
   PubMed Web of Science ®Google Scholar
• Bhasin S, Singh AB, Phong Mac R, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24:299–311
   PubMed Web of Science ®Google Scholar
• Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847–53
   PubMed Web of Science ®Google Scholar
• Morgenthaler A, Bruning CO III, DeWolf WV. Occult prostate cancer in men with low serum testosterone levels. J Am Med Assoc 1996;276:1904–6
   Google Scholar
• Zhang PL, Rosen S, Veeramachanemi R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179–293
   PubMed Web of Science ®Google Scholar
• Hoffmann MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824–7
   PubMedGoogle Scholar
• Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testos- terone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670–5
   PubMed Web of Science ®Google Scholar
• Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161–5164
   PubMed Web of Science ®Google Scholar
• Moore RA. Benign hypertrophy and carcinoma of the prostate: occurrence and experimental production in animals. Surgery 1944;16:152–67
   Google Scholar
• Jie-ping W, Fang-liu G. The prostate 41–65 years post-castration: an analysis of 26 eunuchs. Chin Med J 1987;100:271–2
   PubMedGoogle Scholar
• Stege R, Carlstrom K. Testicular and adreno- cortical function in healthy men and in men with benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1992;42:357–62
   PubMed Web of Science ®Google Scholar
• Zgliczynski S, Baranowska B, Szymanowski J. Zmiany hormonalne w przeroscie i raku gruczolu krokowego. Endokr Pol 1979;4:319–30
   Google Scholar
• Partin A, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405–9
   PubMed Web of Science ®Google Scholar
• Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987;11:33–40
   PubMed Web of Science ®Google Scholar
• Hammond GL, Kontturi M, Vihko P, Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 1978;9:113–21
   PubMed Web of Science ®Google Scholar
• Matzkin H, Chayen R, Goldfarb H, Gilad S, Braf Z. Laboratory monitoring of androgenic activity in benign prostate hypertrophy treated with a 5α-reductase inhibitor. Clin Chem 1992;38:1304–6
   PubMed Web of Science ®Google Scholar
• Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L, Trichopoulos D. Serum steroids in relation to benign prostatic hyperplasia. Oncology 1997;54:497–501
   PubMed Web of Science ®Google Scholar
• Bartsch W, Becker H, Pinkenburg FA, Krieg M. Hormoneblood levels and their inter- relationships in normal men and men with benign prostatic hyperplasia (BPH). Acta Endocrinol 1979;90:727–36
   PubMedGoogle Scholar
• Kumar VL, Wadhwa SN, Kumar V, Farooq A. Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122–8
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K. Endocrine environment of benign prostatic hyperplasia: prostatic size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995;29:65–8
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1992;42:357–62
   PubMedGoogle Scholar
• Hayami S, Sasagawa I, Nakada T. Influence of sex hormones on prostate volume in men on hemodialysis. J Androl 2000;21:258–61
   PubMedGoogle Scholar
• Suzuki K, Inaba S, Takeuchi H, Takezawa Y, Fukabori Y, Suzuki T. Endocrine environment of benign prostatic hyperplasia – relationships of sex steroid hormone levels with age and the size of the prostate. Nippon Hinyokika Gakkai Zasshi 1992;83:664–71
   PubMedGoogle Scholar
• Ranniko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983; 4:223–9
   PubMedGoogle Scholar
• Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993;159:579–85
   PubMedGoogle Scholar
• Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI. Androgen administration in middle-aged and ageing men: effects of oral tes- tosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119–25
   PubMedGoogle Scholar
• Soygür T, Küpeli B, Aydos K, Küpeli S, Arikan N, Müftüoglu YZ. Effects of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 1996;28:55–9
   PubMedGoogle Scholar
• Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP. Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology 2002;143:4922–33
   PubMed Web of Science ®Google Scholar
• Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, et al. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998;139:874–83
   PubMed Web of Science ®Google Scholar
• Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599–604
   PubMed Web of Science ®Google Scholar
• Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneously quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000;42:45–55
   PubMedGoogle Scholar
• Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulo A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998;76:25–8
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Longcope C. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40–9
   PubMed Web of Science ®Google Scholar
• Schweikert HU, Tunn UW, Habenicht UF, Arnold J, Senge T, Schulze H. Effects of estrogen deprivation on human benign prostatic hyper- plasia. J Steroid Biochem Mol Biol 1993;44:573–6
   PubMed Web of Science ®Google Scholar
• Radlmaier A, Eickenberg HU, Fletcher MS. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double- blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Prostate 1996;29:199–208
   PubMed Web of Science ®Google Scholar
• Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77:375–81
   PubMed Web of Science ®Google Scholar
• Partin AW. Benign prostatic hyperplasia – etio- logy of benign prostatic hyperplasia. In Lepor H, ed. Prostatic Diseases. Philadelphia: WB Saunders, 2000:95–105
   Google Scholar
• Bosch JLHR, Hop WCJ, Niemer QHJ, Bangma CH, Kirkels WJ, Schröder FH. Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. Urology 1994;152:1501–5
   Google Scholar
• Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994;40:341–9
   PubMed Web of Science ®Google Scholar
• Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In Wilson JD, Foster DW, eds. Williams’ Textbook ofEndocrinology. Philadelphia: WB Saunders, 1992:799–852
   Google Scholar
• Mendonca BB, Inacio M, Costa EM, Arnhold IJ, Silva FA, Nicolau W, et al. Male pseudo- hermaphroditism due to steroid 5α-reductase-2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 1996; 75:64–76
   PubMedGoogle Scholar
• Imperator-McGinley J. 5α-reductase-2 defi- ciency. Curr Ther Endocrinol Metab 1997;6:384–7
   PubMedGoogle Scholar
• Imperato-McGinley J, Zhu YS. Androgens and male physiology; the syndrome of 5α- reductase-2 deficiency. Mol Cell Endocrinol 2002; 198:51–9
   PubMed Web of Science ®Google Scholar
• Shape RM. The roles of oestrogen in the male. Trends Endocrinol Metab 1998;9:371–7
   PubMedGoogle Scholar
• Barrett-Connor E, Goodman Gruen D, Patay B. Endogenous sex hormones and cognitive func- tion in older men. J Clin Endocrinol Metab 1999; 84:3681–5
   PubMed Web of Science ®Google Scholar
• Komesaroff PA, Fullerton M, Esler MD, Dart A, Jennings G, Sudhir K. Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 2001;38:1011–16
   PubMed Web of Science ®Google Scholar
• Mukherjee TK, Dinh H, Chaudhuri G, Nathan L. Testosterone attenuates expression of vascular adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 2002; 99:4055–60
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Verhoef P, Gooren LJG, Geleijnse JM, Schouten EG, Stehouwer CDA. Oral and trans- dermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003;168:139–46
   PubMedGoogle Scholar
• Toda K, Okada T, Takeda K, Akira K, Saibara S, Shiraishi M, et al. Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17β- oestradiol to aromatase gene (Cyp19) knockout mice. J Endocrinol 2001;168:455–63
   PubMedGoogle Scholar
• Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;16:1553–60
   Google Scholar
• Orwoll ES. Men, bone and estrogen: unresolved issues. Osteoporos Int 2003;14:93–8
   PubMed Web of Science ®Google Scholar
• Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:4078–88
   PubMed Web of Science ®Google Scholar
• Evans EW, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–49
   PubMed Web of Science ®Google Scholar
• Thomas JL, Mason JI, Brandt S, Norris W. Differ- ences in substrate and inhibitor kinetics of human type 1 and type 2 3β-hydroxysteroid dehydro- genase are explained by the type 1 mutant, H156Y. Endocr Res 2002;28:471–5
   PubMed Web of Science ®Google Scholar
• Shibata A, Garcia MI, Cheng I, Stamey TA, NcNeal JE, Brooks JD, et al. Polymorphisms in the androgen receptor type II 5α-reductase genes and prostate cancer prognosis. Prostate 2002; 52:269–78
   PubMedGoogle Scholar
• Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, et al. Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer. Int J Cancer 2003; 105:480–3
   PubMedGoogle Scholar
• Tayeb MT, Clarc C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003;88:928–32
   PubMed Web of Science ®Google Scholar
• Försti A, Jin Q, Grzybowska W, Söderberg M, Zientek H, Sieminska M, et al. Sex hormone- binding globulin polymorphisms in familial and sporadic breast cancer. Carcinogenesis 2002;23:1315–20
   PubMedGoogle Scholar
• Heald AH, Ivison F, Anderson GS, Cruickshank K, Laing I, Gibson MJ. Significant ethnic varia- tion in total and free testosterone concentration. Clin Endocrinol 2003;58:262–6
   PubMed Web of Science ®Google Scholar
• Elkins DA, Yokomizo A, Thibodeau SN, Schaid DJ, Cunningham JM, Marks A, et al. Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer. Prostate 2003;56:30–6
   PubMed Web of Science ®Google Scholar
• Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen APN, Iacopetta BJ, et al. Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. Clin Endocrinol 2003;88:1653–7
   Google Scholar
• Ghali SA, Gottlieb B, Lumbroso R, Beitel LK, Elhaji Y, Wu J, et al. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutation in subjects with varying degrees of androgen insensi- tivity. Clin Endocrinol Metab 2003;88:2185–93
   Google Scholar
• Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, et al. Steroid hormone geno- types ARStuI and ET325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet 2003;131:91–6
   Google Scholar
• Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003; 12:127–35
   PubMedGoogle Scholar
• Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92:2009–17
   PubMed Web of Science ®Google Scholar
• Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case- control study in China. Cancer Res 2000;1518:5111–16
   Google Scholar
• Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeatsin the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;11:3181–6
   Google Scholar
• Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat poly- morphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85–96
   PubMed Web of Science ®Google Scholar
• Byrne MM, Nieschlag E. Testosterone replace- ment therapy in male hypogonadism. J Endocrinol Invest 2003;26:481–9
   PubMed Web of Science ®Google Scholar
• Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nucleic Acids Res 1998; 26:234–8
   PubMed Web of Science ®Google Scholar
• Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000;164:567–72
   PubMed Web of Science ®Google Scholar
• Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60:839–41
   PubMed Web of Science ®Google Scholar
• Modugno F, Weissfeld JL, Trump DL, Zmada JM, Shea P, Cauley JA, et al. Allelic variants to aromatase and the androgen and estrogen recep- tors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092–6
   PubMedGoogle Scholar
• Terouanne B, Nirdé P, Rabenoelina F, Bourguet W, Sultan W, Auzou G. Mutation of the androgen receptor at animo acid 708 (Gly  Ala) abolishes partial agonist activity of steroidal anti- androgens. Mol Pharmacol 2003;63:791–8
   PubMedGoogle Scholar
• Hardy DO, Scher HI, Bodenreider T. Androgen receptor CAG repeat length in prostate cancer: correlation with age of onset. J Clin Endrocrinol Metab 1996;81:4400–5
   PubMed Web of Science ®Google Scholar
• Chen C, Lamharzi N, Weiss NS, Etzoni R, Dightman DA, Barnett M, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1033–40
   PubMed Web of Science ®Google Scholar
• Hsiao PW, Lin DL, Nakao R, Chang C. The linkage of Kennedy’s neuron disease to ARA 24, the first identified androgen receptor polygluta- mine region-associated coactivator. J Biol Chem 1999;29:20229–34
   Google Scholar
• McPhaul MJ. Androgen receptor mutations and androgen insensitivity. Mol Cell Endocrinol 2002; 198:61–7
   PubMedGoogle Scholar
• Yong EL, Lim LS, Wang Q, Mifsud A, Lim J, Ong YC, et al. Androgen receptor polymorphisms and mutations in male infertility. J Endocrinol Invest 2000;23:537–77
   Google Scholar
• La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77–9
   PubMed Web of Science ®Google Scholar
• Dejager S, Bry-Gauillard H, Bruckert E. A com- prehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002;87:3893–901
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999;53:121–5
   PubMed Web of Science ®Google Scholar
• Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O, et al. Androgen receptor repeat length polymorphism in benign prostatic hyper- plasia (BPH): correlation with adenoma growth. Prostate 1999;41:253–7
   PubMed Web of Science ®Google Scholar
• Dowsing AT, Yong EL, Clark M, McLachlan RI, de Kretser DM, Trounson AO. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 1999; 354:640–3
   PubMed Web of Science ®Google Scholar
• Hiort O, Holterhus PM. Androgen insensitivity and male infertility. Int J Androl 2003;26:16–20
   PubMedGoogle Scholar
• Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. Clin Endocrinol Metab 2003;88:2049–54
   Google Scholar
• Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001;86:4867–73
   PubMed Web of Science ®Google Scholar
• Von Eckardstein S, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effec- tiveness of hormonal male contraception. Clin Endocrinol 2002;57:647–55
   PubMedGoogle Scholar
• Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Gene 2000;26:29–36
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E. The CAG repeat poly- morphism in the androgen receptor gene affectsbone density and bone metabolism in healthy males. Clin Endocrinol 2001;55:649–58
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the androgen receptor modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003;46:31–9
   PubMed Web of Science ®Google Scholar
• Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, et al. Develop- ment of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 2003;284:E1009–W1017
   Google Scholar
• Seidmann SN, Araujo AB, Roose SP, McKinlay JB. Testosterone concentration, androgen receptor polymorphism, and depressive symp- toms in middle-aged men. Biol Psychiatry 2001; 50:371–6
   PubMedGoogle Scholar
• Härkönen K, Huhtaniemi I, Mäkinen J, Hübler D, Irjala K, Koskenvuo M, et al. The polymorphic androgen receptor gene CAG repeat, pituitary- testicular function and andropausal symptoms in aging men. Int J Androl 2003;26:187–94
   PubMedGoogle Scholar
• Lehmann DJ, Butler HT, Warden DR, Combrinck M, King E, Nicoll JAR, et al. Asso- ciation of the androgen receptor CAG repeat polymorphism with Alzheimer’s disease in men. Neurosci Lett 2003;340:87–90
   PubMedGoogle Scholar
• Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003;169:1312–15
   PubMed Web of Science ®Google Scholar
• Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, et al. Phenotypic manifesta- tions associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females; a clinical and molecular study of 30 families. Neuromusc Disord 2000;10:391–7
   PubMedGoogle Scholar
• Kritivas K, Yurgalevitch SM, Mohr BA. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endo- crinol 1999;162:137–42
   Google Scholar
• Zitzmann M, Nieschlag E. The CAG repeat polymorphism with the androgen receptor gene and maleness. Int J Androl 2003;26:76–83
   PubMedGoogle Scholar
• Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, et al. Therapeutic perspective. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:3435–48
   PubMed Web of Science ®Google Scholar
• Hershberger JG, Shipley EG, Meyer TK. Myo- trophic activity of 19-nortestosterone and other steroids determined by a modified levator ani method. Proc Soc Exp Biol 1953;83:175–80
   PubMed Web of Science ®Google Scholar
• Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999;54:3459–62
   Google Scholar
• Zhi L, Martinborough E. Selective androgen receptor modulators (SARMs). In Doherty AM, ed. Annual Reports in Medicinal Chemistry. San Diego: Academic Press, 2001;36:169–80
   Web of Science ®Google Scholar
• Elbers JMH, Grootenhuis AJ. New tissue- selective androgens: perspectives in the treatment of androgen deficits. Ann Endocrinol 2003;64:183–8
   PubMedGoogle Scholar
• Anderson RA, Wallace A, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7α-methyl-19- nortestosterone in hypogonadal men. Clin Endocrinol 2003;88:2784–93
   Google Scholar
• Lutz LB, Jamnongjit M, Yang WH, Jahani D, Gill A, Hammes SR. Selective modulation of genomic and nongenomic androgen receptor ligands. Mol Endocrinol 2003;17:1106–16
   PubMed Web of Science ®Google Scholar
• Tremblay RR, Morales AJ. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998;1:213–18
   Google Scholar
• Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000;172:220–4
   PubMedGoogle Scholar
• Weidner W, Behre H, Beutel M, Brahler E, Hertle L, Krause W, et al. The Ageing Male. A Consensus Statement from the Joint Multi- disciplinary Working Group of the German Society of Andrology, the German Society ofDermatology, the German Society of Endo- crinology and the German Society of Urology. Urol Int 2001;66:160–1
   PubMedGoogle Scholar
• Andropause. Consensus Panel. Proceedings of the Andropause Consensus Panel. The Endocrine Society from 2001; cited by 142
   Google Scholar
• Valenti G, Bossoni S, Giustina A, Maugeri D, Motta M, et al. Consensus document on substitu- tion therapy with testosterone in hypoandrogenic elderly men. GISEG (Italian Study Group on Geriatric Endocrinology). Aging Clin Exp Res 2002;14:439–64
   PubMedGoogle Scholar
• Petak SM, Nioukiu HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association for Clinical Endocrinologists AACE guidelines for evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract 2002;8:439–55
   Google Scholar
• Guay AT, Spark RF, Bansal S, Cunningham GR, Goodman NF, Nankin HR, et al. American Asso- ciation of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple’s problem – 2003 update. Endocrine Practice 2003;9:77–95
   PubMedGoogle Scholar
• American College of Physicians/American Society of Internal Medicine. Disease Manage- ment Module on Male Hypogonadism from 2002; cited by 142
   Google Scholar
• Kim YC. Hormonal replacement treatment & aging – Asian practical recommendations on testosterone supplementation. Asian J Androl 2003;in press
   Google Scholar
• Morales A, Lunenfeld B. Standards, Guidelines and Recommendations of The International Society for The Study of the Aging Male (ISSAM). Investigation, treatment and monitor- ing of late-onset hypogonadism in males. Official Recommendations of ISSAM. Aging Male 2002; 5:74–86
   PubMedGoogle Scholar